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Abstract
Background: Recent reports show that gene therapy may provide a long-term, safe and effective intervention for human
diseases. In this study, we investigated the effectiveness of adeno-associated virus 2 (AAV2) based human interferon-alpha
(hIFN-a) gene therapy in experimental autoimmune uveoretinitis (EAU), a classic model for human uveitis.
Methodology/Principal Findings: An AAV2 vector harboring the hIFN-a gene (AAV2.hIFN-a) was subretinally injected into
B10RIII mice at two doses (1.5610
6 vg, 1.5610
8 vg). AAV2 vector encoding green fluorescent protein (AAV2.GFP) was
used as a control (5610
8 vg). The expression of hIFN-a in homogenized eyes and serum was detected by ELISA three
weeks after injection. The biodistribution of vector DNA in the injected eyes, contralateral eyes and distant organs was
determined by PCR. EAU was induced by immunization with IRBP161–180 three weeks following vector injections, and
evaluated clinically and pathologically. IRBP-specific proliferation and IL-17 expression of lymphocytes from the spleen
and lymph nodes were assayed to test the influence of the subretinal delivery of AAV2.hIFN-a on the systemic immune
response. hIFN-a was effectively expressed in the eyes from three weeks to three months following subretinal injection of
AAV2.hIFN-a vector. DNA of AAV2.GFP was observed only in the injected eyes, but not in the distant organs or
contralateral eyes. Subretinal injection of both doses significantly attenuated EAU activity clinically and histologically. For
the lower dose, there was no difference concerning lymphocyte proliferation and IL-17 production among the AAV2.hIFN-
a, AAV2.GFP and PBS injected mice. However, the higher dose of AAV2.hIFN-a significantly suppressed lymphocyte
proliferation and IL-17 production.
Conclusions/Significance: Subretinal delivery of AAV2.hIFN-a lead to an effective expression within the eye for at least
three months and significantly attenuated EAU activity. AAV2.hIFN-a was shown to inhibit the systemic IRBP-specific
immune response.
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Introduction
Uveitis is a common eye disease [1] and is one of the major
causes of blindness worldwide [2]. It manifests either as an isolated
intraocular inflammation or as a part of systemic autoimmune
diseases such as Behcet’s disease, systemic sarcoidosis or ankylosing
spondylitis. Corticosteroids and immunosuppressive agents are
commonly used for the treatment of uveitis. However, long-term
application of these drugs frequently leads to numerous side
effects. Furthermore, there are still a number of patients who do
not respond to immunosuppressive treatment.
The introduction of biologic agents such as tumor necrosis
factor-alpha (TNF-a) antibodies and interferon alpha (IFN-a)
provides a new intervention regimen for patients with refractory
uveitis [3,4,5]. IFN-a has been shown to have multiple
immunoregulatory and immunosuppressive effects [6]. It helps
to upregulate Tregs and inhibits IL-17-expressing cells in patients
with Behcet’s disease and other immune-related disorders [7,8,9].
Others found that it could suppress synthesis of IL-17 in both
PBMCs and Th17 cells [10]. The capability of IFN-a in blocking
IL-17, to some extent, is associated with the upregulation of Tregs
and this may be one of the possible pathways in the treatment of
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                    autoimmunity diseases. However, potential side effects of these
biologic agents have limited their use [3,4]. The improvement of
ocular gene transfer techniques and the application of viral vectors
allow the therapeutic transgene to target the eye and are
considered to overcome these drawbacks.
Currently, gene therapy has achieved remarkable success in
human and animal models in various retinal diseases
[11,12,13,14]. The eye is a suitable organ for gene therapy [15]
because of its following features. The small size and enclosed
structure allow low dose administration to achieve a therapeutic
effect. The convenient access and various routes of vector delivery
can be used to target different layers in the eye [16]. In addition,
many eye examination methods are currently available to monitor
the treatment. Although recent studies have shown that immune
responses can be generated after intraocular administration of
AAV vector, this dose not necessarily to inhibit transgene
expression nor dose it create retinal toxicity [17,18].
Although AAV-mediated gene therapy of retinal disease caused
by single-gene defects has been undergoing clinical trials [19], only
few studies have been attempted in the EAU modal [20,21]. We
have developed a recombinant AAV2 vector containing the
human IFN-a gene. After subretinal injection of the recombinant
vectors into B10RIII mice, sufficient marked expression of this
therapeutic molecule was associated with an attenuated develop-
ment of EAU, a classic model for human uveitis.
Materials and Methods
Ethics Statement
This study was carried out according to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research. The
protocol was approved by the Ethics Committee of the First
Affiliated Hospital of Chongqing Medical University, Chongqing,
China (Permit Number: 2009-201009). All surgery was performed
under anesthesia, and all efforts were made to minimize animal
suffering.
Animals and Reagents
B10RIII mice were purchased from Jackson Laboratory (Bar
Harbor, ME). All animals were housed under standard (specific
pathogen free) conditions. Human interphotoreceptor retinoid
binding protein peptide spanning amino acid residues 161–180
(IRBP161–180, SGIPYIISYLHPGNTILHVD) was synthesized by
Shanghai Sangon Biological Engineering Technology & Services
Ltd. Co. Complete Freund’s adjuvant (CFA) containing 1.0 mg/
ml mycobacterium tuberculosis (H37RA, ATCC 25177) was
obtained from Sigma-Aldrich (St. Louis, MO).
Vectors
The recombinant adeno-associated virus vector harboring
human interferon alpha 2a gene (AAV2.hIFN-a) was prepared
as follows. Total mRNA was extracted from freshly isolated
human PBMCs using RNeasy Plus Mini Kit (QIAGEN, Valencia,
CA) and first-strand cDNA was synthesized with the Superscript
III Reverse Transcriptase system (Invitrogen, Carlsbad, CA,
USA). The coding sequence of human interferon alpha 2a was
obtained from GenBank database (http://www.ncbi.nlm.nih.gov/
genbank/, GenBank accession number BC074936) and the
specific primers were designed (forward, 59 GGGGTAC-
CATGGCCTTGACCTTTGCTTT 39 and reverse, 59 CTG-
TCGACTCATTCCTTACTTCTTAAACTTT 39) to amplify
the human IFN-a coding sequence. The PCR product was
inserted into T vector (T-hIFN-a) and verified by DNA
sequencing on the Applied Biosystems Model 3730 DNA
Sequencing System (Invitrogen Biotechnology Co., Shanghai,
China). The hIFN-a coding sequence was cut from T-hIFN-a with
KpnI and SalI, and subcloned into an AAV2-CMV backbone
between the sites of KpnI and SalI. After sequence verification,
hIFN-a was driven by a human cytomegalovirus (CMV)
intermediate-early promoter and followed by BGH poly A. The
expression cassette was flanked by AAV2 inverted terminal repeats
(ITRs) (Figure 1). Large-scale production and purification of
vectors were performed by Vector Gene Technology Company
Ltd. Vector AAV2.GFP served as a control. Titer of vectors
batches were 3610
11 vg/ml for AAV2.hIFN-a and 1610
12 vg/ml
for AAV2.GFP, respectively.
Subretinal injection
Subretinal injection was performed according to the method
described previously [22]. All procedures were performed under
sterile conditions. Under a dissecting microscope, an aperture
within the dilated pupil area was made through the cornea with a
30-gauge needle, and a blunt 33-gauge needle was inserted
through the corneal opening, avoiding damage to the lens and
penetrating the neuroretina. A total amount of 0.5 ml of vector
suspension or PBS was slowly delivered into the subretinal space
with the aid of a micro-injection system. The successful delivery of
vector was confirmed by partial retinal detachment. All animals
received antibiotic ointment to the cornea and were observed daily
after operation. The retinal detachment resolved spontaneously.
The damages occasionally induced by ocular injection included
temporal corneal edema, iris-cornea adhesion or iris hemorrhage
and cataract formation. The animals with any of these
complications were excluded from further study.
Human interferon-a immunoassay
Mice were sacrificed at various time points following
subretinal injection of AAV2.hIFN-a. The undiluted serum
was collected for assay of hIFN-a. For ocular fluid samples,
AAV2.hIFN-a-injected eyes and contralateral eyes were enucle-
ated respectively. The conjunctival tissues were carefully
removed and the globes were briefly sonicated with homogeniz-
ing solution(20% glycerol, 10 mM KCl, 2 mM MgCl2,0 . 1 %
Triton, 300 mM NaCl, 0.5 mM dithiothreitol, 20 mM HEPES
and Anti-protease Complete TM cocktail in H2O, 10 ml/mg).
After centrifugation at 120006g for 5 min, supernatants from
homogenized eyes were collected. All procedures were conducted
on ice. hIFN-a concentration was determined using a VeriKine
Human IFN Alpha ELISA Kit according to the manufacturer’s
instructions (PBL Interferon Source, USA) with a detection limit
of 12.5 pg/ml.
Figure 1. Scheme of the AAV2.hIFN-a construct. The hIFN-a
coding sequence is under the control of a CMV promoter and followed
by BGH poly (A). The expression cassette is flanked by ITRs. CMV
promoter, human cytomegalovirus immediate early promoter; hIFN-a,
human interferon-alpha; BGH poly (A), BGH poly-adenylation signal; ITR,
AAV2 inverted terminal repeats.
doi:10.1371/journal.pone.0019542.g001
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PCR analysis was performed to evaluate the biodistribution of
rAAV2 vector DNA. Mice were sacrificed and total DNA was
extracted from AAV2.GFP injected eyes, contralateral eyes and
distant organs using a Qiagen DNeasy kit. Primers for GFP
(forward, 59 TGGCCCGCCTGGCATTATGC 39; reverse, 59
TGGAGACTTGGAAATCCCCGTGAGT 39) and GAPDH
(forward, 59 TGACGTGCCGCCTGGAGAAA 39; reverse,
59AGTGTAGCCCAAGATGCCCTTCAG 39) were used to
amplify 750 bp and 98 bp fragments respectively.
Induction and clinical assessment of EAU
Mice were immunized subcutaneously at the base of the tail and
both thighs with 50 mg human IRBP161–180 peptide in 100 ml PBS,
emulsified 1:1 v/v in complete Freund’s adjuvant (CFA)
supplemented with 1.0 mg/ml Mycobacterium tuberculosis strain
(MTB). A total of 200 ml emulsion was given for one mouse.
EAU activity was examined clinically by slit lamp microscopy from
day 8 to 21 after immunization. The clinical severity of ocular
inflammation was assessed by two independent observers in a
masked manner, and scored on a scale of 0–5 in half-point
increments, according to five separate criteria described previously
[23], with some modifications (table 1).
Histopathology
Eyes were enucleated on day 14 following IRBP immu-
nization and were fixed in 4% buffered formaldehyde for
1 hour at room temperature. Tissues were embedded in
paraffin. Serial 4–6 mm sections were cut through the
papillary-optic nerve axis and stained by haematoxylin and
eosin. At least four sections of each eye cut at different levels
were prepared and evaluated histologically. The intensity of
EAU was graded in a masked fashion on a scale of 0 to 4, as
described earlier [24].
IRBP-specific lymphocyte responses
The spleen and draining lymph nodes were removed from
immunized mice on day 21. A single cell suspension was
prepared by mechanical disruption and followed by a passage
through a sterile stainless steel screen. For proliferation and
cytokines assay, cells (2610
6 cells/ml) were cultured in triplicate
with RPMI 1640 medium (Gibco, Grand Island, NY, USA)
containing 2 mM L-glutamine, 5610-5 M2-ME, 0.1 Mm
nonessential amino acids, 1 mM sodium pyruvate and 10%
FBS in the presence of 10 mg/ml IRBP161–180,1 mg/ml
Concanavalin A (Sigma) or medium alone for 72 hours.
Proliferation was detected by a modified MTT assay using a
cell counting kit (Cell Counting Kit-8; Sigma) as described
previously [25]. IL-17 concentration in the supernatants was
measured using a commercially available ELISA kit according to
the manufacturer’s directions (R&D System, Minneapolis, MN)
with a detection limit of 15 pg/ml.
Statistical analysis
Data are expressed as mean 6 standard deviation (SD). Severity
of EAU was analyzed using the Kruskal-Wallis test followed by the
Mann-Whitney U test with Bonferroni correction. Lymphocyte
proliferation and cytokine production was analyzed using
ANOVA. P,0.05 was considered to be significantly different.
All experiments were repeated at least twice.
Results
hIFN-a expression following subretinal injection of
AAV2.hIFN-a vector
Different groups of mice were injected subretinally with two
doses of AAV2.hIFN-a,1 . 5 610
8 vg or 1.5610
6 vg. The hIFN-a
level in supernatants from homogenized eyes was assayed by
ELISA. In the eye receiving a subretinal injection of the higher
dose of AAV2.hIFN-a (1.5610
8 vg), expression of hIFN-a was
detectable on day 14 (mean 4.41 ng/ml) increasing further on
day 21 (mean 7.8 ng/ml). A high level of hIFN-a was observed
on day 42 (10.15 ng/ml) and remained detectable until three
months after injection (the last detection point). For the lower
dose (1.5610
6 vg), the level of hIFN-a was 0.128 ng/ml on day
14, 0.25 ng/ml on day 21, sharply increased on day 42 (mean
1.067 ng/ml) and day 90 (mean 3.057 ng/ml) following
subretinal injection (Figure 2). The hIFN-a expression in the
low dose of AAV2.hIFN-a injected group was about thirty
fold lower than that from the high dose injected group.
For both doses of AAV2.hIFN-a,h I F N - a expression was
undetectable in the undiluted serum or contralateral uninjected
eyes over time.
Biodistribution of vector DNA
PCR analysis was performed to determine the biodistribution of
vector DNA after AAV2.GFP subretinal delivery. Total DNA was
extracted from the injected eyes, contralateral eyes and distant
organs (liver, spleen, heart, brain, lung and kidney) three weeks
after subretinal injection. AAV2 vector DNA was PCR-amplified
using GFP-specific primers. A 750 bp GFP-specific product was
only detected in the AAV2.GFP treated eyes and no PCR product
could be measured in the other tested organs or contralateral eyes
(Figure 3).
Table 1. Criteria of EAU Clinical Scoring in B10RIII mice.
Criteria
Corneal edema Mild +
Moderate ++ Total 15 ‘‘+’’
Gross +++
Conjunctival
hyperemia
Mild +
Moderate ++ Grade:
Gross +++ 0
Ciliary injection
of the cornea
Mild + 11 ,3‘ ‘ +’’
Moderate ++ 24 ,6‘ ‘ +’’
Gross +++ 37 ,9‘ ‘ +’’
Anterior chamber
inflammation
Occasional
cells present
+ 41 0 ,12 ‘‘+’’
Moderate or
heavy cells present
++ 51 3 ,15 ‘‘+’’
Hypopyon or exudate
in the chamber
+++
Posterior
synechiae
Mild (,1/4 of
Posterior synechiae)
+
Moderate(1/4,1/2
of Posterior synechiae)
++
Total seclusion
of the pupil
+++
doi:10.1371/journal.pone.0019542.t001
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All normal B10RIII mice immunized with 50 mg human
IRBP161–180 peptide emulsified in CFA developed EAU as
evidenced by conjunctival hyperemia, ciliary injection, corneal
edema, posterior synechiae, aqueous flare and cells. The
inflammatory signs appeared on day 8 or 9 after immunization,
reached a peak by day 12 and were followed by a gradual
regression. There was no inflammation in the control mice which
received CFA alone.
To test the effect of AAV2.hIFN-a on EAU, it was subretinally
injected into right eyes at two doses, 1.5610
8 vg and 1.5610
6 vg.
AAV2.GFP (5610
8 vg) was injected into the contralateral eyes as
internal control [20]. Mice were immunized with IRBP161–180
peptide emulsified in CFA three weeks after subretinal injection.
Mice receiving a subretinal injection of PBS and a subsequent
immunization with IRBP161–180 peptide emulsified in CFA served
as a separate control group.
Clinical signs were monitored after immunization by slit lamp
microscopy. In PBS or AAV2.GFP injected eyes, severe uveitis, as
evidenced by conjunctival hyperemia, ciliary injection, corneal
edema, aqueous cells and posterior synechiae was observed
(Figure 4A, B). A minor inflammatory reaction as manifested by
conjunctival hyperemia or ciliary injection was found in both
doses of AAV2.hIFN-a treated eyes (Figure 4C, D). Severity of
inflammation was clinically scored on a scale from 0 to 5. Both
doses of AAV2.hIFN-a treated eyes showed a significantly
decreased activity of EAU throughout the course of disease as
compared with PBS or AAV2.GFP injected controls (Figure 4E).
Clinical scoring on day 12 showed that a significantly decreased
severity of EAU was observed in AAV2.hIFN-a
low and
AAV2.hIFN-a
high treated groups when compared with PBS and
AAV2.GFP injected controls (p,0.0001). There was no signif-
icant difference between the two groups receiving different doses
of AAV2.hIFN-a. Histological examination on day 14 showed
severe intraocular inflammation in the AAV2.GFP injected eyes
and PBS injected control mice as evidenced by massive
infiltration of inflammatory cells into the iris, vitreous cavity,
throughout all retinal layers and the choroid, intensive retinal
vasculitis, obvious iris thickening, destruction of the retinal
architecture with severe retinal folding and detachment, as well as
photoreceptor damage (Figure 5A, C). However, in both doses of
AAV2.hIFN-a treated eyes, only scattered infiltration of inflam-
matory cells into the vitreous body and retina was observed
(Figure 5E, G). Additionally, the inflammatory changes in the
anterior segment in both doses of AAV2.hIFN-a treated groups
were less than those in the AAV2.GFP injected eyes and PBS
injected mice (Figure 5B, D, F, H). Pathological grading showed
that PBS injected eyes (EAU grade, 3.0860.66) and AAV2.GFP
treated eyes (EAU grade, 3.260.76) had significantly more
intensive inflammation as compared to the AAV2.hIFN-a treated
eyes (1.3360.6 for low dose, 1.460.58 for high dose) (P,0.0001)
(Figure 5I).
Effects of subretinal injection of rAAV2.hIFN-a on the
IRBP-specific systemic immune response
To determine whether there was an effect of AAV2.hIFN-a on
the IRBP-specific immune response, lymphocytes from spleen
and lymph nodes were isolated and incubated for 72 hours in
vitro with IRBP161–180 peptide, ConA (positive control), or
medium alone (negative control) respectively. The proliferation
and IL-17 production of lymphocytes were assayed. The result
showed a similar response in proliferation and IL-17 production
of lymphocytes incubated with ConA among the two doses of
AAV2.hIFN-a treated mice, AAV2.GFP treated mice and PBS
treated mice. A somewhat lower response in IL-17 production
and proliferation of lymphocytes was observed in all the tested
four groups when exposed to IRBP161–180 peptide. There was no
difference concerning IRBP-specific lymphocyte proliferation and
IL-17 production among lower dose of AAV2.hIFN-a treated
mice, AAV2.GFP treated mice and PBS treated mice (p.0.05).
However, the higher dose of AAV2.hIFN-a treated mice
exhibited significantly reduced IRBP-specific lymphocyte prolif-
eration as compared with PBS treated mice (p=0.012),
AAV2.GFP treated mice (p=0.019) and lower dose of AAV2.
hIFN-a treated mice (p=0.027) (Figure 6A). Also, IL-17
production was significantly downregulated in the group of mice
receiving the higher dose of AAV2.hIFN-awhen compared with
PBS treated mice (p=0.025), AAV2.GFP treated mice (p=0.013)
or mice receiving the lower dose of AAV2.hIFN-a (p=0.018)
Figure 3. Biodistribution of vector DNA three weeks after the
subretinal injection of AAV2.GFP. Vector DNA is detectable only in
the injected eye, but not in the contralateral eye and distant tissues
including liver, spleen, brain, heart, lung, and kidney.
doi:10.1371/journal.pone.0019542.g003
Figure 2. The expression of transgenes following subretinal
injection of AAV2.hIFN-a. The ocular hIFN-a levels at various time
points show that hIFN-a expression starts before day 14 following
injection (the first time point tested). For the higher dose, hIFN-a
expression reaches a peak on day 42 and remains high until day 90. In
the eyes receiving a lower dose of vector, hIFN-a level shows an
unremitting increase from three weeks to three months. Results are
expressed as the mean 6 standard deviation.
doi:10.1371/journal.pone.0019542.g002
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show a detectable proliferation and IL-17 production when
cultured with medium alone.
Figure 4. Clinical evaluation of EAU activity. Two doses of
AAV2.hIFN-a were subretinally injected into the eye respectively, PBS
and AAV2.GFP were used as controls. Three weeks after injection, EAU
was induced by immunization with IRBP161–180 and ocular inflammation
was examined by slit lamp microscopy. Images show significantly
severe inflammation in the PBS (A) and AAV2.GFP injected eyes (B) as
compared to the AAV2.hIFN-a treated eyes (C, D). Kinetics of EAU (E)
reveals that subretinal injection of both doses of AAV2.hIFN-a
persistently attenuated ocular inflammation of EAU as compared with
PBS and AAV2.GFP. The significant difference was observed consecu-
tively on day 11 to 14 after immunization (P,0.05). Data are presented
as mean 6 standard deviation. Clinical score on day 12 after
immunization (F) shows that the PBS injected eyes had a score of 3
(60.58) and the AAV2.GFP injected eyes reached a mean clinical score
of 3.13 (60.77), the score of AAV2.hIFN-a treated eyes was 1.54 (60.69,
p,0.0001, Mann-Whitney U test) in the lower dose treated group and
1.292 (60.45, p,0.0001) in the higher dose group. Each point
represents an individual eye. The average scores of each group are
denoted by the horizontal bars.
doi:10.1371/journal.pone.0019542.g004
Figure 5. Histological examinations on day 14 of EAU. Images of
histological analysis show obvious iris thickening, severe retinal folding,
destruction, damage of the photoreceptor layer and massive inflam-
matory cell infiltration in the iris, vitreous, retina, and subretinal space,
as well as intensive vasculitis formation in PBS injected eye (A, B) and
AAV2.GFP injected eyes (C, D). However, a minor infiltration of
inflammatory cells was observed in the vitreous and retina in both
lower (E, F) and higher dose (G, H) of AAV2.hIFN-a treated eyes.
(haematoxylin eosin staining, original magnification 6100) Histological
grade (I) shows reduced EAU in both doses of AAV2.hIFN-a treated
groups as compared with PBS injected and AAV2.GFP injected eyes
(p,0.0001, Mann-Whitney U test). Each point is the score of an
individual eye. The mean scores of each group are denoted by the
horizontal bars.
doi:10.1371/journal.pone.0019542.g005
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In this study, we investigated the effect of an AAV2-based
ocular gene therapy designed to make retinal cells secrete a
therapeutic molecule, hIFN-a, on the development of EAU in
mice. The results showed an effective expression of hIFN-a within
the treated eyes following subretinal injection of AAV2.hIFN-a.
The distribution of vector DNA was restricted to the injected eye
without detectable spreading. Subretinal administration of
AAV2.hIFN-a using either a high or low dose of vector
(1.5610
8 vg and 1.5610
6 vg), both significantly reduced EAU
development. The IRBP-specific immune response was not
affected following the lower dose vector injection but both
IRBP-specific proliferation and IL-17 production were downreg-
ulated when the higher vector dose was used.
In an attempt to achieve a successful gene therapy, an effective
recombinant viral vector and a feasible gene delivery system in
association with a locally effective expression of transgene without
Figure 6. Systemic IRBP-specific immune responses in each group. IRBP-specific lymphocyte proliferation (A) and IL-17 production in vitro (B)
show no significant difference among lower dose of AAV2.hIFN-a, PBS and AAV2.GFP treated mice (P.0.05). A significant decline of lymphocyte
proliferation is observed in higher dose of AAV2.hIFN-a treated mice compared with PBS injected (p=0.012), AAV2.GFP injected (p=0.019) and lower
dose of AAV2.hIFN-a treated mice (p=0.027). Similarly, the IL-17 production is significantly downregulated in higher dose of AAV2.hIFN-a treated
mice as compared with PBS injected (p=0.025), AAV2.GFP injected (p=0.013) and lower dose of AAV2.hIFN-a treated mice (p=0.018). Results are
presented as mean 6 standard deviation and every experiment was performed three times.
doi:10.1371/journal.pone.0019542.g006
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prepared the recombinant viral vector encoding hIFN-a,a n
effective immune suppressive cytokine, based on adeno-associated
virus, which has been proven to effectively transduce various
ocular cell types for a long time. Subretinal injection of
AAV2.hIFN-a using two doses resulted in the effective secretion
of this cytokine within ocular tissues for at least 70 days.
Examination by fluorescence microscopy showed that GFP was
expressed by RPE cells and photoreceptors following subretinal
injection of AAV2.GFP (data not shown), which are consistent
with earlier reports [26,27]. Expression of GFP within the retina
suggested that hIFN-a might be secreted predominantly by RPE
and cells in the photoreceptor layer. An earlier study by Lai et al
[28] revealed that the secreted protein could diffuse into both the
posterior and anterior segments of the eye with the natural fluid
flow following subretinal injection of AAV2 vectors. It is,
therefore, not surprising to note a strikingly diminished inflam-
matory activity both in the anterior and posterior segments in the
AAV2.hIFN-a treated eyes following immunization with IRBP161–
180 peptide. Another important factor for a successful gene therapy
using viral vectors is that the administrated vector should be
distributed only in the local tissue [29]. In order to examine
whether the injected AAV2 vector entered into other organs, we
investigated its dissemination in the contralateral eye and organs
distant to the injected site. The result showed that the AAV2
vector DNA was found only in the treated eye but not in the tested
organs or in the contralateral eye. This result is consistent with
earlier reports in rats [30] and nonhuman primates [31] and this
has been attributed to the integrity of the blood-eye barrier.
However, early reports showed that AAV2 vector DNA was also
detectable in the brain of intravitreally injected dogs [32] and mice
[33,34]. This result has been explained by the transport of the
AAV2 vector DNA into the brain due to an extremely abundant
expression of this DNA in the ganglion cells following intravitreal
injection [32]. The experiments with subretinal injection of the
recombinant AAV2 vector reported previously by others and the
result presented here seem to avoid this unwanted distribution of
the injected virus DNA into other organs. It is, therefore,
reasonable to presume that subretinal injection of AAV2.hIFN-a
may lead to a long-term effect of hIFN-a within the treated eye
without, at least, obvious systemic biodistribution of AAV2 vector
DNA.
As mentioned above, subretinal injection of AAV2.hIFN-a
could lead to a therapeutic concentration of hIFN-a within the eye
and was able to significantly inhibit EAU elicited by IRBP
administration in the presence of CFA. We subsequently
investigated whether a local administration of AAV2.hIFN-a
affected the IRBP-specific systemic immune response and whether
the inhibitory effect on EAU was associated with a downregulated
IRBP-specific systemic immune response. As there was no tracing
technique available in this experiment, we adopted a two-dose
strategy to identify whether there was a difference in the IRBP-
specific systemic immune response as well as an inhibitory effect
on EAU following subretinal administration. Our result showed
that both doses were able to significantly attenuate the EAU
activity although the hIFN-a expression within the eye of the lower
dose of AAV2.hIFN-a injected group was thirty-fold lower than
that in the higher dose group. A downregulated lymphocyte
proliferation and a decreased IL-17 production were only
observed in the group of animals receiving the higher dose.
However, biodistribution detection showed no dissemination of
AAV2 vector DNA in systemic organs and hIFN-a in serum.
Additionally, early study showed that subretinal administration of
AAV2 vector did not trigger any humoral immune response [27].
Collectively, a likely explanation is that the local immunomodu-
latory environment in the high dose treated animals is causing
local antigen presenting cells to have a less activated phenotype, so
that when they migrate to the draining lymph nodes, the T-cells
are not as activated and perhaps more anergic or tolerant. In view
of these results, it is not likely that the inhibitory effect of hIFN-a
on EAU was mediated by a downregulated systemic immune
response. However, the downregulated systemic immune response,
on one hand, may be useful for uveitis associated systemic diseases.
On the other hand, it may lead to unknown and unwanted side
effects. More studies are needed to explore and address these
issues.
There are some limitations in our study. The production of
hIFN-a was only followed for a time period of three months and a
prolonged observation is needed to determine the duration of
secretion of the transgene product after intraocular administration.
Furthermore, the exact mechanisms by which the released hIFN-a
exactly inhibits EAU should be explored. In addition, a more
effective rAAV2 vector using a promoter modulating the
expression of hIFN-a needs to be developed for future studies.
In conclusion, we have now developed an AAV2-mediated
long-lasting and effective hIFN-a gene delivery system. The locally
secreted hIFN-a following subretinal injection of AAV2.hIFN-a
significantly reduced the activity of EAU.
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